Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Elise R VenableDong ChenConstance P ChenKurt R BessonenPhuong L NguyenJennifer L OliveiraKaaren K ReichardJames D HoyerSimon D AlthoffDana J RohMechelle A MillerKebede BegnaMrinal M PatnaikMark R LitzowAref Al-KaliDavid S ViswanathaRong HePublished in: American journal of clinical pathology (2021)
SF3B1 mutations occur in the full spectrum of myeloid disorders. We independently validated the favorable prognostication of IWG-PM-defined SF3B1-mut-MDS. However it may not provide sharp prognostication within MDS-SF3B1 where IPSS-R and TF comutations were prognostic-informative. Larger cohort studies are warranted to verify these findings and refine MDS-SF3B1 prognostication.